-
公开(公告)号：US20230230668A1
公开(公告)日：2023-07-20
申请号：US18155215
申请日：2023-01-17
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Rangarajan NARAYANASWAMI , Yibin ZHENG , Ashutosh ZADE , Jason O'CONNOR
CPC classification number: G16H20/17 , A61M5/1723 , A61M5/142 , A61M2205/52 , A61M2005/14208 , A61M2230/201
Abstract: Disclosed herein are systems and methods for providing safeguards, in an automatic drug delivery system, to prevent or compensate for insufficient delivery of bolus doses of a liquid drug. The safeguards include, for example, features built into the medication delivery algorithm to allow the medication delivery algorithm to ensure that proper bolus doses are delivered, either manually by the user or automatically by the drug delivery system. In addition, various methods are described for providing the medication delivery algorithm with a means for determining when a meal has been ingested and, in some embodiments, for providing an automatic bolus dose of the liquid drug in response to the determination.
-
公开(公告)号：US20230095302A1
公开(公告)日：2023-03-30
申请号：US17935483
申请日：2022-09-26
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Bonnie DUMAIS , Jason O'CONNOR , Yibin ZHENG
Abstract: Disclosed are techniques and devices that are operable to receive one or a number of generalized parameters of an automated insulin delivery algorithm. An input of at least one generalized parameter corresponding to a user may be used to set one or more of the number of specific parameters of the automated insulin delivery algorithm based on the inputted at least one generalized parameter. Physiological condition data related to the user may be collected. The automated insulin delivery algorithm may determine a dosage of insulin to be delivered based on the collected physiological condition. Signals may be output to cause a liquid drug to be delivered to the user based on an output of the automated insulin delivery algorithm related to the determined dosage of insulin.
-
公开(公告)号：US20230067014A1
公开(公告)日：2023-03-02
申请号：US17821989
申请日：2022-08-24
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , John D'ARCO , David NAZZARO , Yibin ZHENG , Jason O'CONNOR
Abstract: The exemplary embodiments may account for a change in potency of a medicament and adjust the dosage of medicament delivered to a user via a medicament delivery device to compensate for the change in potency. The medicament delivery device may determine the amount of change in the potency in the medicament and may make the adjustment in dosage of the medicament delivered to the user automatically without user input. The net result in that the dosage of medicament delivered to the user is better matched to the user's true need for the medicament.
-
74.发明申请公开(公告)号：US20230062884A1
公开(公告)日：2023-03-02
申请号：US17821994
申请日：2022-08-24
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Yibin ZHENG , Jason O'CONNOR , M. Thomas ANDERSEN
Abstract: Disclosed are processes and techniques for a drug delivery system to maintain optimal drug delivery for a patient according to a treatment plan. The disclosed techniques enable a drug delivery system to delivery adjusted drug dosages and/or drug delivery cost function aggressiveness factors modified based on clusters or patterns of patient drug dosages and/or response event probabilities. For example, a controller for operating a drug delivery device may operate to determine a plurality of dosage clusters for a patient based on drug dosage patient information, determine an adjustment profile for each of the dosage clusters, determine a current cluster for a dosage cycle, determine an adjusted dosage for the dosage cycle by applying the adjustment profile to a default dosage, and provide a signal to the drug delivery device to deliver the adjusted dosage to the patient for the dosage cycle. Other embodiments are described.
-
75.发明申请公开(公告)号：US20230001088A1
公开(公告)日：2023-01-05
申请号：US17848673
申请日：2022-06-24
Applicant: INSULET CORPORATION
Inventor： Ashutosh ZADE , Yibin ZHENG , Joon Bok LEE , Jason O'CONNOR
Abstract: The switchover between an expiring on-body medicament delivery device and a replacement on-body medicament is made to eliminate or significantly decrease the time where an on-body medicament delivery device is operational to deliver medicament to a user. The replacement on-body medicament device is attached to the user and prepped for operation while the expiring on-body medicament delivery device is still operational. The switchover between on-body sensors also may be improved. Methods for calibrating a replacement on-body sensor while the expiring on-body sensor is still operative are provided. The calibrating may be performed quickly so that there is no gap in operation between expiration of the expiring on-body sensor and full operation of the replacement on-body sensor.
-
Patent Agency Ranking
公开(公告)号：US20220395637A1
公开(公告)日：2022-12-15
申请号：US17839645
申请日：2022-06-14
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Jason O'CONNOR
Abstract: The disclosed embodiments are directed to methods for determining, based on input from a manual insulin delivery device, for example, an insulin pen, a proper bolus dosing to be delivered by an AID system, to assess the sufficiency of the user-administered basal dose of long-acting insulin and to recommend any changes to the long-acting delivery following a daily analysis of the user's blood glucose readings.
-
公开(公告)号：US20220392603A1
公开(公告)日：2022-12-08
申请号：US17834332
申请日：2022-06-07
Applicant: INSULET CORPORATION
Inventor： Ashutosh ZADE , Joon Bok LEE , Yibin ZHENG
Abstract: Described are techniques, processes, devices, computer-readable media that enable provision of an indication of whether it is safe for a person with diabetes to participate in exercise while using a wearable drug delivery system. A processor may receive or obtain physiological data related to a condition of a wearer of the wearable drug delivery system and by evaluating an exercise model that uses inputs related to the physiological data to make the determination of whether it is safe to exercise and output an exercise safety signal. Modifications to the wearer's medication treatment plan and other actions may be based on an outputted exercise safety signal.
-
78.发明申请公开(公告)号：US20220193337A1
公开(公告)日：2022-06-23
申请号：US17554514
申请日：2021-12-17
Applicant: Insulet Corporation
Inventor： Matthew ALLES , Joon Bok LEE
Abstract: The exemplary embodiments may provide a smartwatch or a vehicle infotainment system with management and data inspection capabilities for a medicament delivery system. A user may view medicament delivery history and analyte level history via the smartwatch or auto mobile infotainment system. In addition, a user may calculate a medicament dosage and prompt delivery of the medicament bolus dosage via the smartwatch or vehicle infotainment system. Notifications also may be delivered to the user via the smartwatch and vehicle infotainment system.
-
公开(公告)号：US20220168505A1
公开(公告)日：2022-06-02
申请号：US17534129
申请日：2021-11-23
Applicant: Insulet Corporation
Inventor： Mengdi LI , Yibin ZHENG , Joon Bok LEE , Jason O'CONNOR
IPC: A61M5/172
Abstract: Processes and devices are disclosed that are configured to respond to changes in a user's blood glucose caused by ingestion of a meal. Ingestion of the meal may be announced by a user input or by a meal detection algorithm that requires no user input. The responsive device and processes determine a carbohydrate-compensation insulin dosage based on a user's blood glucose history, external data related to the user's meal history, or based on a user's response to previous carbohydrate-compensation insulin dosages. In addition, a correction insulin dosage may be calculated to cover any gap between a starting blood glucose and a target blood glucose. A user's response to a sum of the carbohydrate-compensation insulin dosage and the correction insulin dosage may be delivered. Based on the user's response, the disclosed examples may determine modifications to the carbohydrate-compensation insulin dosage, the correction insulin dosage, or both.
-
公开(公告)号：US20220088303A1
公开(公告)日：2022-03-24
申请号：US17027191
申请日：2020-09-21
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Yibin ZHENG , Steven CARDINALI , Jason O'CONNOR
Abstract: Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.
-
-
-
-
-
-
-
-
-
Search Results
111
records
(took 0.021 seconds)
